Colchicine reduced atherothrombotic cardiovascular events in the COLCOT and LoDoCo2 studies.
US Food and Drug Administration approved colchicine as the first anti-inflammatory drug for
cardiovascular diseases on June, 2023. However, there is a lack of evidence for colchicine in
East Asian population with coronary heart disease, and its effectiveness and safety need
further exploration. Therefore, this study aims to use different doses of colchicine to treat
patients with coronary heart disease after percutaneous coronary intervention, explore the
effects of different doses of colchicine on hsCRP levels, and find the optimal dose of
colchicine for treating coronary heart disease in China.